Ryan Haumschild, PharmD, MS, MBA

Summary for Physicians Neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN) are chronic, often progressive tumors that can lead to significant morbidity due to disfigurement, pain, neurologic impairment, and risk of malignant transformation (MPNST). Mortality is primarily associated with MPNST, which occurs […]

Summary for Physicians Plexiform neurofibromas (PN) in NF1 are typically congenital but often become clinically apparent in early childhood, with growth accelerating during childhood and adolescence. Hallmark symptoms include disfiguring soft tissue masses, pain, neurological deficits, and compression of adjacent

Panelists discuss how mutations in the NF1 gene lead to loss of neurofibromin function, resulting in hyperactivation of the RAS/MAPK and PI3K/AKT/mTOR pathways, and how this molecular dysregulation drives abnormal cell proliferation and tumor development in NF1. Source link Ryan

Summary for Physicians NF1 is predominantly diagnosed in early childhood, typically between ages 4 and 6. Diagnosis is based on NIH clinical criteria, which include: ≥6 café-au-lait macules, ≥2 neurofibromas or 1 plexiform neurofibroma (PN), axillary or inguinal freckling, optic

Video content above is prompted by the following: How common is recurrence of uncomplicated UTIs across various patient populations, and what factors contribute most to recurrences despite adherence to standard treatments? Source link Ryan Haumschild, PharmD, MS, MBA

Video content above is prompted by the following: What role does patient education play in reducing the incidence and recurrence of uncomplicated UTIs, and how can we enhance this aspect of care? Source link Ryan Haumschild, PharmD, MS, MBA

Video content above is prompted by the following: What current trends in the incidence of uncomplicated UTIs are you observing in your practice? Source link Ryan Haumschild, PharmD, MS, MBA

Video content above is prompted by the following: How do social determinants such as socioeconomic status, access to health care, and geographic location affect the prevalence and treatment outcomes in patients with uncomplicated UTIs? Source link Ryan Haumschild, PharmD, MS,

Video content above is prompted by the following: McMichael: How do you see treatment algorithms changing with the introduction of JAK inhibitor therapies? How do you think payers should anticipate covering AA in the next few years? Friedland: What do

Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude I’d like to get final thoughts from each of you. Source link Ryan Haumschild, PharmD, MS, MBA